



PRESS RELEASE

09 October 2024 10:00:00 CEST

AcouSort to showcase its unique AcouTrap technology at two EV conferences

During the first half of October, AcouSort will participate in two conferences: the DSEV conference in Denmark and the MOVE conference in Serbia. Both conferences focus on the very exciting developments in research in extracellular vesicles (EV).

First up was the DSEV conference organized by the Danish Society for Extracellular Vesicles. The conference gathers the Danish research community working with EVs and is a great way for AcouSort to meet and socialize with the researchers. This year, the AcouSort team will exhibit the AcouTrap 3 system and present its great potential in EV isolation.

On October 8-11, AcouSort is attending the MOVE Conference in Belgrade, Serbia, a conference that gathers researchers from all across Europe. The MOVE conference is jointly organized by all the European extracellular vesicle societies, a consortium that has joined forces to foster “MObility for VEsicle research in Europe” (MOVE). The overarching objective is to encourage communication between the societies at all levels of membership. By using the advantage of geographical proximity, MOVE aims to promote EV research and expertise across Europe and across different biological/biomedical disciplines.

“The two conferences provide a great opportunity for us to expand our network within the EV community as well as showcasing our unique AcouTrap technology,” says Agnes Michanek, Commercial Director at AcouSort.

FOR FURTHER INFORMATION ABOUT ACOUSORT, PLEASE CONTACT:

Torsten Freltoft, CEO

Telephone: +45 2045 0854

E-mail: torsten.freltoft@acousort.com

ABOUT ACOUSORT

AcouSort AB (corporate registration number 556824-1037) is an innovative technology company focusing on developing products and solutions for integrated preparation of biological samples. With the help of sound waves, the company's products can separate blood cells, concentrate, purify, and stain cells, exosomes, and bacteria from biological samples. The technology of the company's products is acoustofluidics, where sound waves and microfluidics enable automated handling of samples in a range of application areas, from research on new biomarkers to the development of new diagnostic systems for near-patient testing – so-called Point-of-Care (POC) systems. The company's commercialization strategy is based on the already proven business model of providing separation modules to diagnostic system manufacturers for integrated sample preparation as well as to continue the commercialization of the company's research instruments. With the help of the company's products and development of point-of-care tests, new diagnostic systems and treatments are enabled, addressing some of the most challenging disease areas of our time: cancer, infectious diseases, and cardiovascular diseases. AcouSort is listed at Nasdaq First North Growth Market. The company's Certified Adviser is Carnegie Investment Bank AB (publ).